# Evaluation of the Relationship Between ABCG2 Mutation and Teriflunomide Exposure and Safety in Chinese RMS Patients Treated With Teriflunomide 14 mg Once Daily for 24 Weeks

> **NCT04410965** · PHASE4 · COMPLETED · sponsor: **Sanofi** · enrollment: 82 (actual)

## Conditions studied

- Multiple Sclerosis

## Interventions

- **DRUG:** TERIFLUNOMIDE

## Key facts

- **NCT ID:** NCT04410965
- **Lead sponsor:** Sanofi
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-05-20
- **Primary completion:** 2021-07-12
- **Final completion:** 2021-07-12
- **Target enrollment:** 82 (ACTUAL)
- **Last updated:** 2025-09-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04410965

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04410965, "Evaluation of the Relationship Between ABCG2 Mutation and Teriflunomide Exposure and Safety in Chinese RMS Patients Treated With Teriflunomide 14 mg Once Daily for 24 Weeks". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT04410965. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*